Test Price
2,800 AED✅ Home Collection Available
PSEN2 Gene Alzheimer Disease Type 4 (AD4) Genetic Test in UAE – 2,800 AED – DHA Licensed
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity – Guaranteed via ISO‑Accredited NGS Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary post‑test telephone genetic counselling session to interpret results with a specialist.
- Insurance: Direct billing verification via WhatsApp – +971 54 548 8731.
This Next‑Generation Sequencing (NGS) test decodes the entire coding region of the PSEN2 gene to identify pathogenic variants causing early‑onset familial Alzheimer disease type 4 (AD4). With a turnaround time of just 3–4 weeks, the report provides actionable data for neurological risk assessment, family planning, and personalised anti‑aging strategies.
Test Overview & Methodology
The test employs Next‑Generation Sequencing (NGS) covering all exons and flanking splice sites of the PSEN2 gene, enabling detection of single nucleotide variants, small insertions/deletions, and copy‑number variations with >99% sensitivity. Bioinformatic analysis uses validated pipelines aligned to GRCh38/hg38, and all pathogenic variants are confirmed by Sanger sequencing when necessary.
| Feature | Our Test – NGS Full Gene | Closest Alternative – Targeted Panel |
|---|---|---|
| Methodology | NGS – entire PSEN2 gene, all exons ± splice sites | Sanger sequencing of pre‑selected hot‑spot mutations |
| Detection Rate | >99% of all pathogenic and novel variants | Detects only common founder mutations (~60–70%) |
| Turnaround | 3–4 Weeks | 2–3 Weeks |
| Clinical Actionability | Comprehensive; suitable for diagnosis, risk assessment, and research | Limited; may miss rare/novel mutations → false reassurance |
Physician Insight & Safety Protocols
“Genetic testing for PSEN2 offers clarity for families affected by early‑onset Alzheimer’s, but it is not a crystal ball. A positive mutation indicates increased lifetime risk, not certainty, while a negative result does not eliminate the role of other genes or lifestyle factors. I strongly advise pairing this test with a comprehensive neurological evaluation and never making life‑altering decisions without expert genetic counselling.”
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Safety Advisory – Pre‑Test Precautions
Important Safety Information
Do not discontinue any prescribed medication, including Alzheimer’s therapies, cognitive enhancers, or antidepressants, without explicit instruction from your treating physician. This test is a risk assessment tool, not a therapeutic directive.
- Exclusion criteria: Active severe infection, coagulopathy (INR >1.5 without clearance), inability to provide venous blood sample. For dried blood spot collection, patients on anticoagulants must inform the phlebotomist.
- Red‑Flag Symptoms: If you experience syncope, uncontrolled bleeding, or signs of infection (fever, redness, swelling) at the draw site within 48 hours, seek emergency medical attention.
Exclusion Criteria & Contraindications
This test is not recommended for individuals with active severe systemic infection, known bleeding disorders (INR >1.5 without medical clearance), or inability to provide a venous blood sample. Patients on anticoagulant therapy must consult their haematologist prior to blood draw. Genetic testing for minors requires parental or guardian consent in accordance with UAE law.
Patient FAQ & Clinical Guidance
1. What does the PSEN2 gene Alzheimer disease type 4 NGS test detect?
The test identifies all pathogenic or likely pathogenic mutations in the PSEN2 gene linked to early‑onset familial Alzheimer disease, enabling precise risk stratification. It covers the entire coding region and splice junctions to capture even rare variants.
2. How accurate is this PSEN2 NGS compared to standard genetic screens?
Our full‑gene NGS achieves >99.9% analytical sensitivity and specificity, capturing even rare copy‑number variations and deep intronic splice variants that targeted panels miss. All reported variants are confirmed by orthogonal methods as needed.
3. Who should consider PSEN2 Alzheimer genetic testing in the UAE?
Any adult with a strong family history of early‑onset dementia (before age 65), especially in multiple generations, or individuals seeking proactive neurological and anti‑aging risk assessment. Pre‑test genetic counselling is recommended for all candidates.
4. Can I take this test as a preventive measure without symptoms?
Yes, predictive testing is available for asymptomatic adults with a known family mutation. However, it is crucial to undergo pre‑ and post‑test genetic counselling to fully understand the implications, including possible psychological impact and insurance considerations.
5. How long does it take to receive the results?
Turnaround time is 3–4 weeks from sample receipt in the laboratory. A detailed written report including variant classification, clinical significance, and recommended follow-up actions will be provided.
UAE Regulatory & Data Privacy Adherence
This diagnostic service operates in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and the Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow the provisions of Federal Decree‑Law No. 4 of 2016 on Medical Liability. All genetic data is handled under strict confidentiality protocols, encrypted in transit and at rest, and accessible only to authorised clinical personnel. The laboratory is ISO 15189:2012 accredited (Cert: INT/EGQ/2509DA/3139) and adheres to CAP/CLIA standards. For any data privacy concerns, contact our Data Protection Officer via WhatsApp +971 54 548 8731.
Clinical & Logistical Metadata
| Test Name | PSEN2 Gene Full Gene Sequencing – Early Onset Alzheimer Disease Type 4 (AD4) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole blood (EDTA) – 3–5 mL. VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily 8 AM–11 PM. |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full gene, all exons ± intronic flanking regions |
| ICD-10-CM Code | G30.0 (Alzheimer's disease with early onset), G30.9 (Alzheimer's disease, unspecified) |
| LOINC Code | 93935-7 (PSEN2 gene mutation analysis in blood or tissue by NGS) |
| DHA Facility License & Laboratory Address | Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians